KR20010080927A - 8-시아노-1-사이클로프로필-7-(1s,6s-2,8-디아자비사이클로[4.3.0]노난-8-일)-6-플루오로-1,4-디하이드로-4-옥소-3-퀴놀린 카복실산의 결정 개질체 b - Google Patents
8-시아노-1-사이클로프로필-7-(1s,6s-2,8-디아자비사이클로[4.3.0]노난-8-일)-6-플루오로-1,4-디하이드로-4-옥소-3-퀴놀린 카복실산의 결정 개질체 b Download PDFInfo
- Publication number
- KR20010080927A KR20010080927A KR1020017005420A KR20017005420A KR20010080927A KR 20010080927 A KR20010080927 A KR 20010080927A KR 1020017005420 A KR1020017005420 A KR 1020017005420A KR 20017005420 A KR20017005420 A KR 20017005420A KR 20010080927 A KR20010080927 A KR 20010080927A
- Authority
- KR
- South Korea
- Prior art keywords
- ccdc
- diazabicyclo
- cyclopropyl
- dihydro
- oxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (10)
- X-선 분말 디프랙토그램(X-ray powder diffractogram)이 하기 고(high) 및 중간(medium) 세기의 반사 시그널(2 세타)을 나타냄을 특징으로 하는 결정 개질체 B의 8-시아노-1-사이클로프로필-7-(1S,6S-2,8-디아자비사이클로[4.3.0]노난-8-일)-6-플루오로-1,4-디하이드로-4-옥소-3-퀴놀린카복실산(CCDC):
- X-선 분말 디프랙토그램이 하기 고 및 중간 세기의 반사 시그널(2 세타)을 나타내고, DTA 에 의해 측정된 융점이 243 내지 245 ℃임을 특징으로 하는 결정 개질체 B의 8-시아노-1-사이클로프로필-7-(1S,6S-2,8-디아자비사이클로[4.3.0]노난-8-일)-6-플루오로-1,4-디하이드로-4-옥소-3-퀴놀린카복실산(CCDC):
- 하기 일반식 (II)의 7-할로게노-8-시아노-1-사이클로프로필-6-플루오로-1,4-디하이드로-4-옥소-3-퀴놀린카복실산을, 경우에 따라 염기의 존재하에 N-메틸-피롤리돈, 디메틸포름아미드 및 설폴란과 같은 극성 비양성자성 희석제와 혼합된 에탄올중에서 하기 구조식 (III)의 (1S,6S)-2,8-디아자비사이클로[4.3.0]노난과 반응시키거나,미지 개질체의 CCDC를, 경우에 따라 염기의 존재하에 에탄올, 프로판올 또는 이소프로판올과 같은 희석제중에서, 또는 이들 알콜과 N-메틸-피롤리돈, 디메틸포름아미드 또는 설폴란과 같은 극성 비양성자성 희석제의 혼합물중에서 가열한 후, 혼합물을 냉각하고, 결정 개질체 B의 CCDC를 분리함으로써 수득될 수 있는 결정 개질체 B의 8-시아노-1-사이클로프로필-7-(1S,6S-2,8-디아자비사이클로[4.3.0]노난-8-일)-6-플루오로-1,4-디하이드로-4-옥소-3-퀴놀린카복실산(CCDC):상기 식에서, Hal 은 불소, 또는 바람직하게는 염소를 나타낸다.
- 하기 일반식 (II)의 7-할로게노-8-시아노-1-사이클로프로필-6-플루오로-1,4-디하이드로-4-옥소-3-퀴놀린카복실산을, 경우에 따라 염기의 존재하에 N-메틸-피롤리돈, 디메틸포름아미드 및 설폴란과 같은 극성 비양성자성 희석제와 혼합된 에탄올중에서 하기 구조식 (III)의 (1S,6S)-2,8-디아자비사이클로[4.3.0]노난과 반응시키거나,미지 개질체의 CCDC를, 경우에 따라 염기의 존재하에 에탄올, 프로판올 또는 이소프로판올과 같은 희석제중에서, 또는 이들 알콜과 N-메틸-피롤리돈, 디메틸포름아미드 또는 설폴란과 같은 극성 비양성자성 희석제의 혼합물중에서 가열한 후, 혼합물을 냉각하고, 결정 개질체 B의 CCDC를 분리함을 특징으로 하여 제 1 항 내지 제 3 항중의 어느 하나에 따른 결정 개질체 B의 CCDC를 제조하는 방법:상기 식에서, Hal 은 불소, 또는 바람직하게는 염소를 나타낸다.
- 제 4 항에 있어서, 사용된 용매가 에탄올인 경우, N-메틸-피롤리돈, 디메틸포름아미드 또는 설폴란이 추가의 용매로서 사용됨을 특징으로 하는, 개질체 B의 CCDC를 제조하는 방법.
- 제 4 항에 있어서, 사용된 용매가 에탄올인 경우, N-메틸-피롤리돈이 추가의 용매로서 사용됨을 특징으로 하는, 개질체 B의 CCDC를 제조하는 방법.
- 제 4 항에 있어서, 사용된 염기가 트리메틸아민, 트리에틸아민 또는 에틸디이소프로필아민임을 특징으로 하는, 개질체 B의 CCDC를 제조하는 방법.
- 통상적인 보조제 및 부형제와 함께, 제 1 항 내지 3 항중의 어느 하나에 따른 개질체 B의 CCDC를 함유함을 특징으로 하는 약제.
- 약제를 제조하기 위한 제 1 항 내지 3 항중의 어느 하나에 따른 개질체 B의 CCDC의 용도.
- 항박테리아 조성물에 있어서 제 1 항 내지 3 항중의 어느 하나에 따른 개질체 B의 CCDC의 용도.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19854355.7 | 1998-11-25 | ||
DE19854355A DE19854355A1 (de) | 1998-11-25 | 1998-11-25 | Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010080927A true KR20010080927A (ko) | 2001-08-25 |
KR100740950B1 KR100740950B1 (ko) | 2007-07-19 |
Family
ID=7888959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020017005420A KR100740950B1 (ko) | 1998-11-25 | 1999-11-15 | 8-시아노-1-사이클로프로필-7-(1s,6s-2,8-디아자비사이클로[4.3.0]노난-8-일)-6-플루오로-1,4-디하이드로-4-옥소-3-퀴놀린 카복실산의 결정 개질체 b |
Country Status (29)
Country | Link |
---|---|
US (1) | US6664268B1 (ko) |
EP (1) | EP1133497B1 (ko) |
JP (2) | JP5127094B2 (ko) |
KR (1) | KR100740950B1 (ko) |
CN (1) | CN1150193C (ko) |
AR (1) | AR028467A1 (ko) |
AT (1) | ATE289606T1 (ko) |
AU (1) | AU767890B2 (ko) |
BR (1) | BRPI9915682B8 (ko) |
CA (1) | CA2351707C (ko) |
CZ (1) | CZ300012B6 (ko) |
DE (2) | DE19854355A1 (ko) |
DK (1) | DK1133497T3 (ko) |
ES (1) | ES2237186T3 (ko) |
HK (1) | HK1042705B (ko) |
HU (1) | HU229071B1 (ko) |
IL (2) | IL142695A0 (ko) |
NO (1) | NO318065B1 (ko) |
NZ (1) | NZ511862A (ko) |
PL (1) | PL196078B1 (ko) |
PT (1) | PT1133497E (ko) |
RU (1) | RU2248355C2 (ko) |
SK (1) | SK285554B6 (ko) |
TR (1) | TR200101444T2 (ko) |
TW (1) | TWI245767B (ko) |
UA (1) | UA67873C2 (ko) |
UY (1) | UY25818A (ko) |
WO (1) | WO2000031076A1 (ko) |
ZA (1) | ZA200103187B (ko) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19854356A1 (de) | 1998-11-25 | 2000-05-31 | Bayer Ag | Kristallmodifikation A von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-/4.3.0/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
DE19854355A1 (de) * | 1998-11-25 | 2000-05-31 | Bayer Ag | Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
DE19908449A1 (de) | 1999-02-26 | 2000-08-31 | Bayer Ag | Kristallmodifikation C von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo-[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino/incarbonsäure |
DE19908448A1 (de) | 1999-02-26 | 2000-08-31 | Bayer Ag | Kristallmodifikation D von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo[4.3.0)nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino incarbonsäure |
DE102004015981A1 (de) | 2004-04-01 | 2005-10-20 | Bayer Healthcare Ag | Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
DE102005055385A1 (de) * | 2004-12-09 | 2006-06-14 | Bayer Healthcare Ag | Arzneimittel zur hygienischen Applikation im Ohr |
DE102006049520A1 (de) * | 2006-10-20 | 2008-04-24 | Bayer Healthcare Ag | Verfahren zur Herstellung von Pradofloxacin |
DE102007026550A1 (de) * | 2007-06-08 | 2008-12-11 | Bayer Healthcare Ag | Extrudate mit verbesserter Geschmacksmaskierung |
PE20191462A1 (es) | 2017-02-13 | 2019-10-16 | Bayer Animal Health Gmbh | Composicion liquida que contiene pradofloxacina |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5036099A (en) * | 1987-02-02 | 1991-07-30 | Pfizer Inc. | Anhydrous, crystalline sodium salt of 5-chloro-3-(2-thenoyl)-2-oxindole-1-carboxamide |
JP2676521B2 (ja) * | 1988-03-22 | 1997-11-17 | 北陸製薬株式会社 | キノロンカルボン酸化合物i型結晶の製造法 |
DE3906365A1 (de) * | 1988-07-15 | 1990-01-18 | Bayer Ag | 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe |
DE3910663A1 (de) * | 1989-04-03 | 1990-10-04 | Bayer Ag | 5-alkylchinoloncarbonsaeuren |
JP2832848B2 (ja) * | 1989-10-21 | 1998-12-09 | 株式会社林原生物化学研究所 | 結晶2―O―α―D―グルコピラノシル―L―アスコルビン酸とその製造方法並びに用途 |
BR9509688A (pt) | 1994-11-18 | 1997-09-30 | Upjohn Co | Composto e composição farmacêutica |
DE19546249A1 (de) * | 1995-12-12 | 1997-06-19 | Bayer Ag | Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen |
DE19633805A1 (de) * | 1996-02-23 | 1997-08-28 | Bayer Ag | Gegenenenfalls substituierte 8-Cyan-l-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]-nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäuren und ihre Derivate |
NZ331468A (en) * | 1996-02-23 | 2000-02-28 | Bayer Ag | Substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-[4,3.0]-nonan-8-yl)-6-fluoro-1, 4-dihydro-4-oxo-3-quinolin carboxylic acids and their derivatives |
DE19649681A1 (de) * | 1996-11-29 | 1998-06-04 | Basf Ag | Verfahren zur Herstellung eines kristallinen Feststoffes aus Glycin-N,N-diessigsäure-Derivaten mit hinreichend geringer Hygroskopizität |
DE19854356A1 (de) | 1998-11-25 | 2000-05-31 | Bayer Ag | Kristallmodifikation A von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-/4.3.0/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
DE19854355A1 (de) * | 1998-11-25 | 2000-05-31 | Bayer Ag | Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
DE19908448A1 (de) | 1999-02-26 | 2000-08-31 | Bayer Ag | Kristallmodifikation D von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo[4.3.0)nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino incarbonsäure |
DE19908449A1 (de) | 1999-02-26 | 2000-08-31 | Bayer Ag | Kristallmodifikation C von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo-[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino/incarbonsäure |
-
1998
- 1998-11-25 DE DE19854355A patent/DE19854355A1/de not_active Withdrawn
-
1999
- 1999-11-15 KR KR1020017005420A patent/KR100740950B1/ko active IP Right Grant
- 1999-11-15 PT PT99959278T patent/PT1133497E/pt unknown
- 1999-11-15 AU AU16517/00A patent/AU767890B2/en not_active Expired
- 1999-11-15 NZ NZ511862A patent/NZ511862A/en not_active IP Right Cessation
- 1999-11-15 TW TW088119808A patent/TWI245767B/zh not_active IP Right Cessation
- 1999-11-15 US US09/856,670 patent/US6664268B1/en not_active Expired - Lifetime
- 1999-11-15 CN CNB998136727A patent/CN1150193C/zh not_active Expired - Lifetime
- 1999-11-15 BR BRPI9915682A patent/BRPI9915682B8/pt not_active IP Right Cessation
- 1999-11-15 SK SK683-2001A patent/SK285554B6/sk not_active IP Right Cessation
- 1999-11-15 TR TR2001/01444T patent/TR200101444T2/xx unknown
- 1999-11-15 HU HU0104713A patent/HU229071B1/hu unknown
- 1999-11-15 DE DE59911666T patent/DE59911666D1/de not_active Expired - Lifetime
- 1999-11-15 CZ CZ20011857A patent/CZ300012B6/cs not_active IP Right Cessation
- 1999-11-15 WO PCT/EP1999/008776 patent/WO2000031076A1/de active IP Right Grant
- 1999-11-15 UA UA2001064425A patent/UA67873C2/uk unknown
- 1999-11-15 PL PL347785A patent/PL196078B1/pl unknown
- 1999-11-15 IL IL14269599A patent/IL142695A0/xx active IP Right Grant
- 1999-11-15 RU RU2001117521/04A patent/RU2248355C2/ru active
- 1999-11-15 DK DK99959278T patent/DK1133497T3/da active
- 1999-11-15 CA CA2351707A patent/CA2351707C/en not_active Expired - Lifetime
- 1999-11-15 EP EP99959278A patent/EP1133497B1/de not_active Expired - Lifetime
- 1999-11-15 AT AT99959278T patent/ATE289606T1/de active
- 1999-11-15 ES ES99959278T patent/ES2237186T3/es not_active Expired - Lifetime
- 1999-11-15 JP JP2000583904A patent/JP5127094B2/ja not_active Expired - Lifetime
- 1999-11-22 AR ARP990105938A patent/AR028467A1/es active IP Right Grant
- 1999-11-25 UY UY0001025818A patent/UY25818A/es not_active Application Discontinuation
-
2001
- 2001-04-19 ZA ZA2001/03187A patent/ZA200103187B/en unknown
- 2001-04-19 IL IL142695A patent/IL142695A/en not_active IP Right Cessation
- 2001-05-18 NO NO20012461A patent/NO318065B1/no not_active IP Right Cessation
-
2002
- 2002-06-14 HK HK02104458.5A patent/HK1042705B/zh not_active IP Right Cessation
-
2012
- 2012-07-27 JP JP2012167352A patent/JP2012236841A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012236841A (ja) | 8−シアノ−1−シクロプロピル−7−(1s,6s−2,8−ジアザビシクロ[4.3.0]ノナン−8−イル)−6−フルオロ−1,4−ジヒドロ−4−オキソ−3−キノリンカルボン酸の結晶変態b | |
KR100756471B1 (ko) | 8-시아노-1-사이클로프로필-7-(1s,6s-2,8-디아자비사이클로[4.3.0]노난-8-일)-6-플루오로-1,4-디하이드로-4-옥소-3-퀴놀린 카복실산의 결정 개질체 c | |
US20090012296A1 (en) | Processes for the preparation of crystalline form beta of imatinib mesylate | |
KR100740947B1 (ko) | 8-시아노-1-사이클로프로필-7-(1s,6s-2,8-디아자비사이클로[4.3.0]노난-8-일)-6-플루오로-1,4-디하이드로-4-옥소-3-퀴놀린 카복실산의 결정 개질체 a | |
KR100756474B1 (ko) | 8-시아노-1-사이클로프로필-7-(1s,6s-2,8-디아자비사이클로[4.3.0]노난-8-일)-6-플루오로-1,4-디하이드로-4-옥소-3-퀴놀린 카복실산의 결정 개질체 d | |
KR100740956B1 (ko) | 8-시아노-1-사이클로프로필-7-(1s,6s-2,8-디아자비사이클로[4.3.0]노난-8-일)-6-플루오로-1,4-디하이드로-4-옥소-3-퀴놀린 카복실산의 세미-하이드로클로라이드 | |
MXPA01005229A (en) | Crystal modification b of 8-cyano-1- cyclopropyl -7-(1s,6s-2, 8-diazabicyclo [4.3.0]nonan -8-yl)-6- fluoro-1,4- dihydro-4- oxo-3-quinoline carboxylic acid | |
MXPA01008651A (en) | Crystal modification c of 8-cyano-1-cyclopropyl-7- (1s, 6s-2,8- diazabicyclo -[4.3.0]nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic | |
MXPA01005230A (en) | Crystal modification a of 8-cyano-1- cyclopropyl -7-(1s,6s-2, 8-diazabicyclo [4.3.0]nonan -8-yl)-6- fluoro-1, 4-dihydro- 4-oxo-3- quinoline carboxylic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
FPAY | Annual fee payment |
Payment date: 20130705 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140701 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150630 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160630 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170704 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180628 Year of fee payment: 12 |